Eris Lifesciences acquires nine dermatology brands from Dr Reddy’s for Rs 2,750 mn
Eris entered the dermatology segment through the acquisition of Oaknet Healthcare for Rs 6,500 million in May 2022 and…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s Laboratories
Dr Reddy’s to acquire Mayne Pharma’s US generic prescription product portfolio
Dr Reddy's Laboratories has entered into a definitive agreement to acquire the US generic prescription product portfolio of…
LPC 150 Conclave to be held at NIPER Hyderabad on March 12, 2023
The theme of the event is Pharma 4.0: Digital transformation across pharmaceuticals
Dr Reddy’s Laboratories announces major recognitions in gender equality and sustainability
Included in Bloomberg Gender-Equality Index for sixth year in a row and S&P Global’s Sustainability Yearbook for the third…
Union Budget 2023: Industry lauds focus on R&D
Pharma leaders and experts share their views on Union Budget 2023 and give insights on the impact of the measures
Claims against Dr Reddy’s over Revlimid in US dismissed
On 22nd December, 2022 and 27th December, 2022, the plaintiffs voluntarily dismissed Dr Reddy’s Laboratories Limited and Dr…
Anti-trust litigation filed against Dr Reddy’s Laboratories and other generic pharma companies in US
The complaint seeks damages for purported overpayments and equitable relief
Indian drug 2DG can reduce heart damage by coronavirus, find US researchers
Their findings, based on research with fruit flies and mouse heart cells, were published in 'Communications Biology,' a 'Nature'…
Dr Reddy’s lines up Rs 1,500 crore capex to focus on biosimilars and injectables
The drug major also plans to utilise the capital for adding capacities to existing plants, firm up R&D activities and further…
Dr Reddy’s announces financial results for Q2 and H1 FY23
EBITDA is at Rs 19.3 billion and the EBITDA margin is 30.6 per cent